Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Academy Award winning filmmaker Martin Scorsese ( Taxi Driver , Goodfellas , Killers of the Flower Moon ) has signed on to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.